Cyclohexane Prostacyclin Receptor Modulators for Oral PAH Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary arterial hypertension (PAH) rely on short-acting prostacyclin analogs that require continuous intravenous infusion, posing risks of rebound pulmonary hypertension and catheter-related complications, and there is a need for stable, orally-active prostacyclin analogs for broader disease management.
Innovation Solution
Development of cyclohexane derivatives and their pharmaceutically acceptable salts, solvates, and hydrates that modulate the activity of the PGI2 receptor, offering potential as therapeutically effective agents for PAH and other conditions by providing a stable, orally-active alternative.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If continuous intravenous infusion of prostacyclin analogs is used to treat PAH, then therapeutic effect is maintained, but risk of rebound pulmonary hypertension and catheter-related complications increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of prostacyclin analogs to achieve oral bioavailability and extended half-life. The cyclohexane derivatives with specific substituents (R1, R2, X, R3) represent systematic parameter changes in molecular structure that transform the drug from short-acting IV formulation to stable oral formulation, resolving the contradiction between maintaining therapeutic effect and avoiding infusion-related harms
Solution Approach 2:
The invention replaces the continuous infusion requirement (a complex, high-risk administration method) with a stable oral tablet formulation that can be taken intermittently. This transforms the treatment from a continuous, catheter-dependent therapy to a discrete, oral medication that patients can self-administer, eliminating catheter-related complications and rebound hypertension risks
2Speed
If short-acting prostacyclin analogs are administered, then immediate therapeutic effect is achieved, but frequent dosing and continuous infusion are required
Solution Approach 1:
The patent employs dynamics by designing a drug molecule with optimized pharmacokinetic properties. The cyclohexane derivative structure with specific functional groups enables the drug to maintain active metabolite levels over an extended period while still providing rapid onset of action. This dynamic balance between absorption rate and elimination rate resolves the contradiction between immediate effect and prolonged duration
Solution Approach 2:
The invention achieves continuity of useful action through extended half-life formulation that maintains therapeutic plasma concentrations between doses. The stable oral formulation ensures continuous drug availability in the system without requiring constant re-administration, eliminating treatment gaps while maintaining steady therapeutic effect
3Ease of operation
If orally-active prostacyclin analogs are developed, then ease of administration is improved, but stability and bioavailability challenges must be overcome
Solution Approach 1:
The patent systematically changes molecular parameters of prostacyclin analogs to achieve oral stability. The cyclohexane core with specific substituents (various R groups and X linkages) represents structured parameter optimization that protects the molecule from metabolic degradation while maintaining receptor affinity. This resolves the contradiction between oral administrability and chemical stability by designing molecules that resist breakdown in the gastrointestinal tract and liver
Solution Approach 2:
The invention uses composite molecular structure combining the cyclohexane scaffold with prostacyclin-like functional groups. This composite approach creates a hybrid molecule that incorporates the pharmacophore needed for PGI2 receptor activation while adding structural elements that provide oral stability and bioavailability, resolving the contradiction between ease of administration and molecular stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These cyclohexane derivatives offer a stable, orally-active solution for PAH treatment, potentially reducing the risks associated with continuous infusion and expanding therapeutic applications beyond PAH.
Implementation Method 1
the binding of PGI2 or other such agonist) to the PGI2 receptor leads to coupling with the Gs protein and increases intracellular cAMP levels
Data Source
AI summary
The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: Pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis, atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).